Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Evgen Pharma looks to Spain for latest licensing deal

For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.
Evgen Pharma looks to Spain for latest licensing deal
Evgen has 60 new chemical entities to add to the pipeline.

Evgen Pharma (LON:EVG) has struck an interesting deal with the Spanish National Research Council and the University of Seville.

For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.

Evgen said it will use its Sulforadex platform to synthesise and stabilise the newly acquired compounds.

As well as the upfront payment, the firm’s new partners will receive cash as the drug or drugs hit certain milestones. They will also receive a royalty on any sales that won’t exceed 1%.

Chief executive Stephen Franklin said: “We are delighted to acquire the exclusive worldwide licensing rights to these novel compounds.

“The University of Seville has conducted an innovative medicinal chemistry programme based on sulforaphane and, like sulforaphane, these novel compounds have a requirement for our patented stabilisation technology.

“These new compounds give us the opportunity to lead the intellectual property space around sulforaphane and to build a drug development pipeline targeting several therapeutic markets within neurology and oncology."

View full EVG profile View Profile

Evgen Pharma Timeline

Article
October 21 2015

Related Articles

pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use